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a  b  s  t  r  a  c  t
Background:  Although  the mortality  from  diarrheal  diseases  has  been  decreasing  dramatically  in  Iran,  it
still represents  an important  proportion  of  disease  burden  in  children  <5  years  old.  Rotavirus  vaccines
are  among  the  most  effective  strategies  against  diarrheal  diseases  in  specific  epidemiological  conditions.
This  study  aimed  to  evaluate  the  cost-effectiveness  of  the  introduction  of  rotavirus  vaccine  (3  doses  of
pentavalent  RotaTeq®  (RV5))  in Iran,  from  the  viewpoints  of Iran’s  health  system  and  society.
Methods:  The  TRIVAC  decision  support  model  was used  to calculate  total  incremental  costs,  life years
(LYs)  gained,  and  disability-adjusted  life  years  (DALYs)  averted  due  to  the  vaccination  program.  Necessary
input data  were  collected  from  the most  valid  accessible  sources  as well  as  a  systematic  review  and  meta-
analysis  on  epidemiological  studies.  We  used  WHO  guidelines  to estimate  vaccination  cost.  An annual
discount  rate  of  3% was  considered  for both  health  gain  and  costs.  A  deterministic  sensitivity  analysis
was  performed  for  testing  the  robustness  of the  models  results.
Results:  Our  results  indicated  that  total  DALYs  potentially  lost  due  to  rotavirus  diarrhea  within  10  years
would  be  138,161,  of which  76,591  could  be  prevented  by rotavirus  vaccine.  The  total  vaccination  cost
for  10  cohorts  was  estimated  to be  US$  499.91  million.  Also,  US$  470.61  million  would  be  saved  because
of  preventing  outpatient  visits  and  inpatient  admissions  (cost-saving  from  the society  perspective).  We
estimated  a cost  per  DALY averted  of  US$  2868  for RV5  vaccination,  which  corresponds  to a  highly  cost-
effective  strategy  from  the  government  perspective.  In the  sensitivity  analysis,  all  scenarios  tested  were
still cost-saving  or highly  cost-effective  from  the  society  perspective,  except  in  the least  favorable  scenario
and  low  vaccine  efficacy  and  disease  incidence  scenario.
∗ Corresponding author at: Institute for Health Metrics and Evaluation, University of Washington Seattle, WA 98121, United States. Tel.: +12068973747; fax: +1 2068972899.
E-mail  addresses: m.javanbakht@abdn.ac.uk (M.  Javanbakht), mmoradi@uw.edu, moradi.m@iums.ac.ir (M.  Moradi-Lakeh), mohsenyaq@yahoo.com (M.  Yaghoubi),
steghamati@gmail.com (A. Esteghamati), roxanaghanaie@yahoo.com (R. Mansour Ghanaie), Sussanmahmoody@yahoo.com (S. Mahmoudi), ar shamshiri@yahoo.com
A.-R. Shamshiri), zahraeicdc@yahoo.com (S.M. Zahraei), Louise.Baxter@lshtm.ac.uk (L. Baxter), sarehshakareian@gmail.com (S. Shakerian), CHAUDHRII@emro.who.int
I. Chaudhri), jfleming@path.org (J.A. Fleming), amunier@aamp.org (A. Munier), baradaran.hr@iums.ac.ir (H.R. Baradaran).
ttp://dx.doi.org/10.1016/j.vaccine.2014.12.035
264-410X/© 2014 Elsevier Ltd. All rights reserved.
Downloaded for Anonymous User (n/a) at Iran University of Medical Sciences from ClinicalKey.com by Elsevier on February 02, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
M. Javanbakht et al. / Vaccine 33S (2015) A192–A200 A193
Conclusion:  Based  on  the  findings,  introduction  of  rotavirus  vaccine  is  a  highly  cost-effective  strategy  from
the  government  perspective.  Introducing  the  vaccine  to  the  national  immunization  program  is an  efficient




















































We used the pooled estimate for the weighted median of duration. Introduction
The high prevalence and incidence of diarrhea are recognized
s a major health problem. There were nearly 1.7 billion diar-
hea episodes among children less than 5 years of age in low- and
iddle-income countries in 2010 [1]. Diarrheal disease is also the
econd leading cause of death in children under 5 years old, killing
bout one million children every year [2].
Rotavirus is the most important cause of severe diarrhea
n infants and young children worldwide [3,4]. Rotaviruses are
biquitous, and 95% of children are infected by the age of 5
ears. Rotavirus is responsible for a large proportion of the
bove-mentioned deaths and 20–54% of acute diarrhea episodes
orldwide [5–7].
Eesteghamati and his colleagues [8] reported that rotavirus is
he most important cause of severe diarrhea among hospitalized
hildren aged less than 5 years old in Iran. Those researchers also
ound that rotavirus disease accounts for more than one-half of all
ospitalizations for severe diarrhea.
Recent studies show that rotavirus vaccines might be the best
hoice for preventing severe rotavirus disease and the deadly dehy-
rating diarrhea that it causes, particularly in low-income countries
here access to treatment for RV is limited [9,10]. There are two
otavirus vaccines: the pentavalent RotaTeq® (RV5) (Merck and Co.
nc., West Point, Pennsylvania, USA) and the monovalent Rotarix®
RV1) (GlaxoSmithKline Biologicals, Rixensart, Belgium). Studies
f the rotavirus vaccine have shown that the efficacy of RV5 and
V1, respectively, against rotavirus gastroenteritis of any severity
as 74.0% (95% confidence interval (CI) 66.8–79.9) and 87% (95%
I 79.6–92.1) [11,12]. More importantly, the rotavirus vaccines can
revent approximately 98% of severe infections and 70% to 100% of
mergency department visits and hospitalizations from rotavirus
12–14].
Decisions to adopt vaccination programs depend on multiple
actors, including the disease prevalence and incidence, vac-
ine efficacy, and cost-effectiveness of a vaccination program.
lthough some studies have estimated the cost-effectiveness of
otavirus vaccination [15–18], most of them have been conducted
n developed countries, not in developing nations. Results of cost-
ffectiveness studies can vary among countries due to differences
n epidemiological patterns, patients’ characteristics or health sys-
em variables (such as incidence/prevalence of disease, adherence
o the treatment regimen, individuals’ preferences for particular
evels of health, unit costs of inputs into health care, and varia-
ion in how health care is delivered). Moreover, no simple rule is
vailable to indicate how the results of cost-effectiveness studies in
eveloped countries might translate to health care delivery settings
n developing nations.
The major serotype of rotavirus in Iran is G4P [8] and other
ominant strains are P [8] with G nontypeable, G4 with P non-
ypeable, G1 [P8], and G2 [P4] [8]. Although the major serotype
an be covered by RV1 through cross-reactivity, RV5 provides
irect protection against it. Also, based on a recent systematic
eview, RV5 was used in the unique study that reported vac-
ine efficacy against G4 and P [8] in middle-income countries
19]. Therefore, we conducted this study to evaluate the cost-
ffectiveness of RV5 vaccination compared to no vaccination in
ran.
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2. Methods
2.1. Study design
This economic evaluation was conducted from the perspec-
tives of Iran’s government and its society; in the governmental
perspective, those direct medical costs imposed on governmental
health system were included and in the societal perspective, all
direct medical costs that imposed on society including (patients’
families or government) were included. The TRIVAC model, a
decision-support model developed by the ProVac Initiative of the
Pan American Health Organization (PAHO) in collaboration with the
London School of Hygiene and Tropical Medicine (LSHTM) [20], was
used to calculate total incremental costs, life years gained, disability
adjusted life years (DALYs) averted due to the vaccination program,
and an incremental cost-effectiveness ratio (ICER). A data collection
procedure was used in order to obtain the necessary input data from
the most valid accessible sources for the analysis.
We used the assumptions made by TRIVAC for the natural his-
tory of rotavirus. We  classified rotavirus as non-severe or severe
cases of rotavirus gastroenteritis (RVGE). TRIVAC is a static model
that only crudely takes account of the indirect protection of the
vaccination on unvaccinated children through herd immunity or
of the negative effects of type replacement. A crude multiplier of
direct vaccine efficacy can be applied to replicate a herd effect;
also, vaccine efficacy can be decreased to reflect the circulating
serotypes [20]. We  assumed 2014 as the year of introduction of
the vaccine and included children 1–59 months old for 10 sequen-
tial birth cohorts in the analysis (2014–2023). The time horizon for
health and economic benefits has been defined in the TRIVAC model
specifications [20]. An annual discount rate of 3% was considered
for both health gain and costs.
2.2. Input epidemiological and effectiveness data
2.2.1. Demographic data
The number of live births was derived using data from Iran’s
National Organization for Civil Registration. We  used the last
Multiple-Indicator Demographic and Health Survey (IrMIDHS,
2010) to obtain mortality rates among children [21]. We also used
the United Nations Population Division database to extract the esti-
mates for current life expectancy of women and men in Iran and
also estimates for the future [22].
2.2.2. Disease burden
An epidemiologic model was  used to estimate the incidence of
diarrheal diseases. According to the 2010 Demographic and Health
Survey (DHS) report [21], the 14-day prevalence of all-cause diar-
rhea was 13.5% in Iran (the IrMIDHS study was performed between
22 December 2010 and 20 January 2011). This included all chil-
dren who had a new episode of diarrhea within 14 days before
survey or those whose episode started before the period, but still
were symptomatic during the period. All cases of diarrhea started
within (duration-1) days before the first day of study period, were
among the prevalent cases at least in the first day of the period.of diarrhea in low- and middle-income countries for children 0–59
month old, which was 3.1 days (3.0–3.2) in a systematic review
icalKey.com by Elsevier on February 02, 2020.
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23]. We rounded it to 3 days for calculation purposes. Considering
 3-day duration for all-cause diarrheal diseases, the daily inci-
ence rate was estimated 8.4 per 1000 person-day based on the
 = PP/[study period + (D − 1)] formula, where I, PP and D indicate
ncidence, period prevalence and duration, respectively. Assum-
ng no systematic difference between the study period and whole
alendar year, annual incidence rate of all-cause diarrhea was  esti-
ated to be 307,968 episodes per 100,000 children.
To estimate the proportion of rotavirus diarrhea from all-cause
iarrhea, we used the results of a systematic review and meta-
nalysis [24]. That review included all Iranian studies indexed in
he international and national databases, including PubMed, Ovid
edline, Science Direct, Google Scholar, Institute for Scientific
nformation (ISI), and Scopus as well as Iran Medex and Irandoc
or Farsi-language papers [25]. The systematic review included 21
tudies on hospital cases from 11 different provinces (10,997 cases)
nd 15 studies on outpatient cases from 7 different provinces (4371
ases). For hospital and outpatient settings, the pooled estimates
ith random effect were 39% (95% CI: 32–47%) and 31% (95% CI:
3–38%), respectively. Based on the opinion of clinical expert in
he research team, in our model we used the pooled estimate of
he outpatient setting (31%) as the percentage of all-cause diarrhea
ncidence that is attributable to rotavirus. That is because the inci-
ence in community was the parameter of interest in the model,
ather than hospitalizations.
We estimated the number of deaths attributed to rotavirus diar-
hea based on statistics from the national registry of childhood
eaths. Their database reports cause-specific mortality for children
5 years old, with nationwide coverage. For our estimate, we  mul-
iplied the proportion of severe cases of diarrheal disease that are
ue to rotavirus (39%) by the total number of deaths due to diar-
heal diseases extracted from that national registry. The disability
eight for diarrhea episodes was considered to be 0.119, as used in
he model and the 1st global burden of disease (GBD) study. There
re updated disability weights for diarrheal diseases [26], but we
id not use them, so that our results would be comparable with the
esults of other local and international studies. The age distribution
f disease cases was obtained from an Iranian study on sentinel sites
or rotavirus surveillance [8].
.2.3. Vaccine coverage and efficacy
We assumed that the new vaccine would be administered jointly
ith another vaccine in the routine schedule [27] (DTP vaccine
t 2, 4, and 6 months), with a coverage of 99% and a maximum
chievable coverage of 99.5%. Ministry of Health collects admin-
strative data from all rural health houses and urban health posts
hich are responsible for routine immunization. Those informa-
ion have good consistency with nationally representative surveys
21]. The vaccination coverage of DTP3 and Hepatitis-B3 are around
9% based on estimates of the Ministry. The rotavirus vaccine effi-
acy (VE) has not been reported for Iran. Therefore, three scenarios
ere modeled in order to explore how different scenarios of vac-
ine efficacy would impact the cost-effectiveness profile in Iran,
ased on evidence from countries in the same WHO  mortality
tratum, B (low adult and low children mortality). The first sce-
ario, which was the base-case scenario, incorporated estimates
f three-dose VE of 82.2% (70.0–90.1%) against Vesikari scale ≥11
severe) rotavirus gastroenteritis (RVGE), based on a multi-country
tudy in Latin America [28]. The second scenario used full dose effi-
acy estimates from Vietnam of 63.9% (7.6–90.9%) against severe
VGE. We  also used a very low estimate of VE from the same study
48.3%) in our sensitivity analysis; that was an overall estimate for
ietnam and Bangladesh (WHO mortality stratum B and D, respec-
ively) which is a pessimistic estimate for Iran condition. [29]. The
hird scenario used efficacy estimates from the Linhares et al. Latin
merican study against very severe RVGE (Vesikari scale ≥19) of
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97.3% (83.8–99.9%) [28]. While RV1 was used in this study instead
of RV5, immunogenicity and efficacy estimates for the two  vaccines
are similar across a range of countries [30]. Partial schedule efficacy,
that is, efficacy of only one or two doses (which has been estimated
to take into account drop-outs and children who do not receive their
full schedule), was calculated according to published studies of
Latin America and Asia [28,29]. Efficacy for 1 and 2 doses was equal
to 52% and 71% of full doses, respectively. The ratio of VE of non-
severe (all who need medical attention except admitted) versus
severe cases (admitted) was estimated at 83%, based on the Vesikari
et al. study [11]. The relative coverage of deaths was considered to
be 90%. This is an adjustment that accounts for a concentration of
deaths in the children who  are not reached by vaccination—and so
the true effectiveness may  be lower than the equal distribution of
deaths [31]. The annual decrease in dose efficacy, which was used
to simulate waning protection, was considered to be 4.8% [28]. In
the base-case analysis we  assumed no herd immunity exist. We
tested a 110% multiplier for VE in sensitivity analysis to estimate
the impact of herd immunity. The serotype coverage of RV5 was
considered 100% based on frequency of common serotypes in Iran
[8] and cross-reactivity; in sensitivity analysis, a 52.7% serotype
coverage was tested as low serotype coverage.
2.3. Cost estimation
2.3.1. Vaccination program costs
We used WHO  guidelines [32] to estimate the incremental cost
of introducing the rotavirus vaccine into the current national vac-
cination system. The cost of vaccine supplies was calculated using
the formula of C = P × I ×B ×D × (1/(1 − w)), where P is the vaccine
price per dose, I is the immunization coverage rate, B is the birth
cohort population, D is the number of doses per fully immunized
child, and w is the wastage rate.
The price of each dose (US$ 10) was obtained from the local
representative of the vaccine’s manufacturer. A Ministry of Health
representative provided the company with the number of required
vaccine doses and officially asked about and negotiated on the price.
Finally, we  received a pro forma for the vaccine price. The number
of doses per child fully immunized for rotavirus was considered
as three, and the wastage rate was assumed to be 5%. To esti-
mate the incremental system cost per dose, we  included the cost
of distribution system, cold chain, surveillance monitoring, train-
ing, maintenance, personnel expenses, and the required facilities
that are needed beyond the currently available facilities of Iran’s
Ministry of Health. The total annualized capital cost was estimated
based on equipment prices and their useful life and an annualizing
factor. In addition, health care personnel costs (all heath care work-
ers involved in this program, including vaccinators) were assessed
on the basis of exclusive time allocations for this vaccine and other
incentive payment.
2.3.2. Health service utilization and costs
To estimate the total outpatient health care utilization costs, we
extracted data on health care seeking during an episode of child-
hood diarrhea from a representative nationwide study on 14,625
children with diarrheal diseases [33]. The study showed that 70%
of cases had at least one visit with a health care provider. Those
included visits with a physician in 61.6% of cases and with either
a behvarz (rural health care worker) or a health post officer (non-
physician care provider in urban area) in 8.4% of cases. The rest of
the cases (30%) had not had a visit with any health care provider. The
personnel cost for physicians was  estimated based on a weighted
mean of the official price of outpatient visits of general practitioners
and specialists in private and public sectors.
We estimated the pattern of prescribing diagnostic tests and
medications in severe and non-severe cases by interviewing a wide
ClinicalKey.com by Elsevier on February 02, 2020.
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Table  1
Input parameters for estimating disease burden.
Parameter Estimate Scenarios Source
(s)
Low High
Annual incidence per 100,000 aged 1–59 mo
Rotavirus (non-severe) cases 92,315 68,492 113,160 [21,36]
Rotavirus (severe) cases 2864 2125 3511 [21,36]
% Case fatality ratios (CFRs) in ages 1–59 moa
Rotavirus (severe) cases 0.02% 0.01% 0.03% Child mortality surveillance system of Iran
Disability weight for DALY calculations
Rotavirus (non-severe) cases 0.119 – – [26]
Rotavirus (severe) cases 0.119 – – [26]
Mean duration of illness (in days)
Rotavirus (non-severe) cases 6 – – Assumption
Rotavirus (severe) cases 6 – – Assumption
Age  distribution of disease cases and deaths
<3 mo 2.4% – – [8]
3–5 mo  7.8% – – [8]
6–8 mo  20.0% – – [8]
9–11 mo  20.0% – – [8]
12–23 mo  35.0% – – [8]
24–35 mo  5.0% – – [8]


























48–59 mo  4.8% 
a In the absence of vaccination, CFRs are assumed to decline in each successive b
he  fraction of under-5 deaths caused by the disease remains fixed over time.
ange of health professionals, including general practitioners, pedi-
tric assistants, and pediatricians, in the public and private sectors.
he average cost of each inpatient episode was estimated based
n medical records of 60 patients who were hospitalized for viral
iarrhea (based on ICD-10-CM Diagnosis Code A08) in the Mofid
hildren’s Hospital, in Tehran, Iran, in 2012 (average length of stay
as 3.1 days and mean age was 2.3 years). All costs were estimated
sing 2013 price levels or were inflated from previous years to 2013
alues using the health sector pay and prices index when appropri-
te. To have an international perspective all costs were converted
rom Iranian Rials [IRR] into United State dollars (US$) at an official
013 currency exchange rate of 24,000 IRR per US$ 1.00 [34].
able 2
nput parameters for estimating health service utilization and costs (all costs are presente
Parameter Estimate 
Outpatient visits
Outpatient visits per disease episode
Rotavirus (non-severe) cases 0.70 
Rotavirus (severe) cases 1.00 
Government cost per outpatient visita
Rotavirus (non-severe) cases $2.23 
Rotavirus (severe) cases $4.69 
Household cost per outpatient visitb
Rotavirus (non-severe) cases $3.85 
Rotavirus (severe) cases $6.60 
Inpatient admissions
Inpatient admissions per disease episode
Rotavirus (severe) cases 0.90 
Government cost per inpatient admissionc
Rotavirus (severe) cases $174.52 
Household cost per inpatient admissiond
Rotavirus (severe) cases $45.29 
a Government costs per outpatient visit include visit, medications, and diagnostic tes
ollows:  specialist physician (public: 8%, private: 41%), general practitioner (public: 17%, p
s  the weighted average of the provider-specific costs.
b Household costs per outpatient visit include direct medical cost (out-of-pocket pay
ttention (70%) are distributed as follows: specialist physician (public: 8%, private: 41%), g
ersonnel: 8%. The cost presented is the weighted average of the provider-specific costs.
c Government costs per inpatient admission include direct medical cost [the cost per
isease-specific drugs and diagnostics]. Inpatient admissions are distributed as follows: 4
ost  presented is the weighted average of the provider-specific costs.
d Household costs per inpatient admission include out-of-pocket expenditure for me
istributed as follows: 4.8% social security hospital, 5.2% private hospitals, and 90.0% pu
osts.
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hort in line with the general trend in under-5 mortality. This is done by assuming
2.4. Cost-effectiveness measures and sensitivity analysis
The incremental cost-effectiveness ratio (ICER) of vaccination
versus no vaccination in the base-case scenario was  defined in
terms of the ratio of the difference in costs to the difference in effect
measures ((vaccine cost − cost saving)/DALY averted).
We also defined our threshold (ceiling rate) for labeling an inter-
vention as being cost-effective or not based on WHO  guideline
[35]. We  conducted a series of deterministic sensitivity analyses
to detect those parameters that had the most impact on the ICER,
with different input parameters being changed in a sequence to the
upper and lower limit, while the other variables were held constant.












ts. Outpatient visits in cases who seek medical attention (70%) are distributed as
rivate: 22%), health post officers: 4% and behvarz personnel: 8%. The cost presented
ments for consultations and drugs). Outpatient visits in cases who seek medical
eneral practitioner (public: 17%, private: 22%), health post officers: 4% and behvarz
 bed day multiplied by the expected length of stay (3.1 days) and the cost of any
.8% Social Security hospital, 5.2% private hospitals, and 90.0% public hospitals. The
dical cost of medication, hospital care, and diagnostics. Inpatient admissions are
blic hospitals. The cost presented is the weighted average of the provider-specific
icalKey.com by Elsevier on February 02, 2020.
. Elsevier Inc. All rights reserved.
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Table 3
Input parameters for estimating rotavirus vaccine (RV) coverage and timeliness.
Parameter Estimate (%) Scenarios Source(s)
Low High
Coverage of DTP1 by age in year 2014 (proxy for RV doses given with DTP1)
3  mo 96.2 – – EPI & [37]
6 mo 97.5 – – EPI & [37]
9 mo 97.9 – – EPI & [37]
12 mo 98.3 – – EPI & [37]
24 mo 99.0 – – EPI & [37]
Coverage of DTP2 by age in year 2014 (proxy for RV doses given with DTP2)
3  mo 0.0 – – EPI & [37]
6 mo 97.4 – – EPI & [37]
9 mo 97.6 – – EPI & [37]
12 mo 98.1 – – EPI & [37]
24 mo 99.0 – – EPI & [37]
Coverage of DTP3 by age in year 2014 (proxy for RV doses given with DTP3)
3  mo 0.0 – – EPI & [37]
6 mo 97.0 – – EPI & [37]
9 mo 97.5 – – EPI & [37]
12 mo 98.0 – – EPI & [37]
24 mo 99.0 – – EPI & [37]
Coverage projections over the 2014–2023 period were estimated by assuming RV will achieve the same coverage and timeliness as DTP and by assuming a 5% annual decrease
in  the gap between final coverage in the cohort (coverage by age 24 mo)  and a ceiling of 100% (DTP1), 100% (DTP2), and 100% (DTP3).
Table  4
Input parameters for estimating RV5 program costs.
Parameter Estimate Scenarios Source(s)
Low High
Vaccine dose price projection
2014 $10.00 $7.00 $12.00 Local representative of the manufacturer
2015  $10.00 $7.00 $12.00 Assumption
2016  $10.00 $7.00 $12.00 Assumption
2017  $10.00 $7.00 $12.00 Assumption
2018  $10.00 $7.00 $12.00 Assumption
2019  $10.00 $7.00 $12.00 Assumption
2020  $10.00 $7.00 $12.00 Assumption
2021  $10.00 $7.00 $12.00 Assumption
2022  $10.00 $7.00 $12.00 Assumption
2023  $10.00 $7.00 $12.00 Assumption
Other  vaccine dose costs
International handling (% of vaccine price)a 3.00% 1.00% 5.00% Assumption
International delivery (% of vaccine price)b 2.00% 1.00% 3.00% Assumption
Wastage (% of doses discarded etc.)c 5.00% 3.00% 7.00% Assumption
Incremental system costs of introductiond
Incremental system cost per dose $1.13 $1.02 $1.24 Calculated
a The handling percentage refers to the international service charges (documents, airports).
b Delivery percentage refers to the international shipping cost (international freight), which includes insurance.

















d Estimated incremental system costs include cost of personnel (88.4% of cost), t
f  cost). They are assumed to be recurrent costs each year.
. Results
Input parameters for estimating disease burden, disease-related
ervice utilization and costs, vaccine coverage, vaccination pro-
ram costs, and vaccine efficacy are summarized in Tables 1–5. The
odel’s results for outcomes and costs for 10 cohorts from 2014 to
023 for the entire country are presented below.
.1. Effectiveness measures
As shown in Table 6, without a vaccination program, there would
e 64,464,813 cases of diarrhea over 10 birth cohorts from 2014 to
023, including 62,524,950 non-severe cases and 1939,863 severe
ases. In contrast, with a vaccination program, 35,129,919 cases of
iarrhea could be averted. During this period of time, 266 deaths
ould also be avoided via the vaccination program. Life years gained
hrough vaccination were estimated 7888. Without vaccination,
Downloaded for Anonymous User (n/a) at Iran University of Medical Sciences from 
For personal use only. No other uses without permission. Copyright ©2g material (8.6% of cost), vehicles and transport (1.7% of cost), and cold chain (1.3%
total DALYs lost due to mortality and morbidity from rotavirus diar-
rhea would be 138,161, while vaccination could prevent 76,591 of
them in the same period (Table 6).
3.2. Cost and health care utilization measures
From a societal perspective, our results revealed that within
the modeling time horizon, without vaccination there would be
45,125,369 outpatient visits, of which 24,590,943 could be averted
via vaccination (Table 6). In addition, the total estimated number of
inpatient admissions without vaccination would be 1745,877; 65%
of them (1139,256) could be avoided through vaccination. Based on
the average cost of each outpatient visit, the total cost of outpatient
visits would be US$ 402.08 million without vaccination. Further-
more, the total estimated cost of inpatient admissions would be
US$ 383.76 million. Our results show that about US$ 470.6 mil-
lion would be saved by preventing outpatient visits and inpatient
ClinicalKey.com by Elsevier on February 02, 2020.
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Table  5
Input parameters for estimating the health impact of RV5.
Parameter Estimate (%) Scenarios Source(s)
Low (%) High (%)
Vaccine efficacy vs non-severe RVGE
Dose 1 35.4 19.2 42.6 [11,38]
Dose 2 35.4 35.4 42.6 [11,38]
Dose 3 68.1 37.1 68.1 [11,38]
Vaccine efficacy vs severe RVGE
Dose 1 42.7 41.0 44.1 [28,39]
Dose 2 42.7 42.7 89.4 [28,39]
Dose 3 82.1 63.9 97.0 [28,29]
Other vaccination impact assumptions
%  Vaccine serotype coverage 100 57 100 [8,40]
% Relative coveragea 90 80 100 Assumption
%  Decrease in dose efficacy per yrb 4.8 0.0 5.0 [28]
% Contribution of herd effect in <5 yrc 100 100 110 Assumption
a Relative coverage is the coverage in those at risk of getting the disease (i.e., effective coverage) relative to coverage in the entire birth cohort (i.e., overall coverage).
Overall  coverage is multiplied by relative coverage to obtain a more realistic estimate of effective coverage.
b To account for waning duration of clinical vaccine-induced protection, TRIVAC uses a waning matrix with age bands (<3 mo,  4–5 mo,  6–8 mo,  9–11 mo, 12–23 mo,
24–35  mo,  36–47 mo,  48–59 mo)  repeated in the rows and columns of the matrix. The direct protection at the start of each age band is represented by the diagonal from
top-left  to bottom-right of the matrix. Protection is re-calculated for each age band as the child gets older (moves from left to right in each row). Adjusted protection by age
is  calculated by adding together the revised protection estimates for each column.
c Rather than endogenous modeling of transmission dynamics, the % direct protection <5 yr is multiplied by a herd effect multiplier (e.g., 110%) to give the % total protection
in  the cohort of interest before age 5.0 yr. This excludes any herd effect in individuals aged 5 yr+ and is therefore very conservative.
Table 6
Discounted health benefits (discounted at 3% per year) for 10 cohorts vaccinated






Total cases <5 yr (×1000) 64,465 29,335 35,130
Rotavirus (non-severe) cases (×1000) 62,525 28,661 33,864
Rotavirus (severe) cases (×1000) 1940 674 1266
Total outpatient visits (×1000) 45,125 20,534 24,591
Rotavirus (non-severe) cases (×1000) 43,767 20,063 23,705
Rotavirus (severe) cases (×1000) 1358 472 886
Total inpatient admissions (×1000) 1746 607 1139
Rotavirus (severe) cases (×1000) 1746 607 1139
Total deaths <5 yr 408 142 266





















Discounted economic benefits (costs are discounted at 3% per year) for 10 cohorts






Total gov. health service
costsa (×1000)
453,208 172,937 280,270















Total societal health service
costsb (×1000)
785,841 315,221 470,619















a Government perspective includes all bed day and disease-specific
drug/diagnostic costs borne by the government at the following health providers:
health center, public primary/secondary/tertiary hospital.DALYs lost 138,161 61,569 76,591
Due to morbidity (YLDs) 126,073 57,370 68,703
Due to mortality (YLLs) 12,088 4200 7888
dmissions (Table 7). The total vaccination cost for the 10 cohorts
ould be US$ 499.91 million (Table 8).
.3. Cost-effectiveness estimates
Our final results in this section showed that rotavirus vaccine is a
ighly cost-effective intervention compared to no vaccination from
he government perspective. The estimated cost per DALY averted
as US$ 2868 from the government perspective (Iran’s GDP per
apita as used in the model was equal to US$ 4763). Also from
he government’s perspective, the estimated costs were US$ 27,844
er life-year gained, US$ 825,098 per death averted, US$ 203 per
npatient admission averted, and US$ 6 per case averted. From the
ociety perspective, the estimated cost per DALY averted was  US$
82.
.4. Sensitivity Analysis
The results of the deterministic sensitivity analysis showed that
isease incidence, vaccine price, case fatality ratio, and vaccine effi-
acy were among the most important parameters that can change
he ICER. As shown in Fig. 1, on the basis of the WHO  threshold,
rom both the societal and government perspectives, the rotavirus
accine was not cost-effective in the least favorable scenario for
accine introduction, that is, lowest disease incidence, low vaccine
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In  addition, it includes all household costs incurred when visiting both government
and  private health providers.
efficacy (a 63.9% low and a 48.3% very low estimate), low serotype
coverage, low health care utilization cost, low relative coverage
of death, and highest vaccine price and system costs. In other
cases, the intervention was  always cost-saving, very cost-effective
or cost-effective.4. Discussion
Based on the results of TRIVAC, rotavirus vaccination was highly
cost-effective from the societal and governmental perspective. It
icalKey.com by Elsevier on February 02, 2020.
. Elsevier Inc. All rights reserved.
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Table 8
Discounted cost-effectiveness of RV5 (costs and DALYs discounted at 3% per year)





Cost-effectiveness compared to no
vaccine
Net cost of vaccine introduction
(×1000)
$219,640 $29,291
Costs of vaccine introduction
(×1000)
$499,911 $499,911
Health service costs avoided (×1000) $280,270 $470,619
DALYs averted 76,591 76,591
Due to morbidity (YLDs) 68,703 68,703
Due to mortality (YLLs) 7888 7888
US$ per DALY averted 2868 382
Cost-effectiveness threshold
1 × GDP per capita (2013)—WHO




















3×  GDP per capita (2013)—WHO
threshold for “cost-effective”
$14,289 $14,289
lso will be cost-saving from the government perspective at a vac-
ine price per dose less than US$ 5.2.
Our analysis estimated that vaccination could prevent more
han 35.1 million cases of rotavirus-associated diarrhea within the
tudy time horizon (2014–2023). A national rotavirus immuniza-
ion program was estimated to prevent 65% of all rotavirus-related
eaths. The economic burden of rotavirus-associated hospital-
zations and outpatient visits among children aged less than 5
ears in Iran during the study time horizon was calculated to be
S$ 785.84 million from the societal perspective. About 60% (US$
70.61 million) of this cost could be prevented through vaccina-
ion.
Results of previous studies have shown that rotavirus vac-
ination would be a cost-effective public health intervention in
arious developing countries. For example, in Kenya, Rotarix® and
ig. 1. US$ per DALY averted for base case RV5 scenario and alternative “what-if” scenario
isease  incidence, low serotype coverage, low death coverage, low vaccine efficacy (64%
rice  and system cost. (2) b Favorable scenario = high disease incidence, high serotype cov
igh  relative coverage of death, and low vaccine price and system cost. (*) Scenario is cos
he  government and households) exceeds the cost of introducing the vaccine.
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RotaTeq® have a cost-effectiveness ratio of US$ 142 and 288 per
DALY averted from a societal perspective [41]. In Vietnam, univer-
sal vaccination of infants at a cost of US$ 7.26 or less per vaccine
dose would be a cost-effective public health intervention [42].
In Thailand, as part of the national immunization program, the
rotavirus vaccine would be cost-effective at the price of US$ 6.20 per
dose; at a maximum vaccine price of US$ 6.20–10.50 per dose, the
cost-effectiveness ratio is approximately US$ 185–759 per DALY
averted [43]. In Uzbekistan, rotavirus vaccination could be cost-
effective with vaccine prices in the range of US$ 2–25 per child
[44].
One study evaluated the cost-effectiveness of introducing
rotavirus vaccination in GAVI-eligible countries [9]. The results
showed that in a baseline scenario with an initial vaccine price of
US$ 7 per dose for a 2-dose vaccine, and with a gradual decrease in
vaccine price over time, vaccination was  highly cost-effective in all
the GAVI-eligible countries, based on their GDP-based thresholds.
In addition, a national rotavirus immunization program for Brazil-
ian children would be cost-saving with a price less than US$ 2.2 per
dose [45].
The estimated ICER in our study is higher than in most of the
other developing countries. This can be explained partially by a
low case fatality ratio of rotavirus in Iran, a lower level of health
care utilization in terms of frequency and intensity, and a higher
vaccine price.
Although a rotavirus vaccine program has the potential to be
cost-effective, cost-effectiveness results should be interpreted with
consideration to country-specific comparators for improving the
health of children. For instance, there are other completed or
undergoing studies in Iran on the cost-effectiveness of vaccines
against Haemophilus Influenzae type b [46], pneumococcal diseases,
influenza virus, and acellular pertussis. All these vaccines could
possibly be introduced to the national program of immunization
[27]. Sustainability is another important issue for introducing a new
vaccine, and it can be influenced by such factors as vaccine price,
s: government perspective and societal perspective.(1) a Unfavorable scenario = low
), low health care utilization cost, low relative coverage of death, and high vaccine
erage, high death coverage, high vaccine efficacy, high health care utilization cost,
t-saving from a societal perspective, i.e., the health service costs avoided (by both
ClinicalKey.com by Elsevier on February 02, 2020.
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vailability of financial resources in the health system, and country
otential for technology transfer.
Using local cost and epidemiological data in our analysis is a
ood base for local health policy-making. However, there are some
imitations in the study. We  made several assumptions that could
ffect the results of the analysis. We  estimated the case fatality
atio in severe cases at 0.02%, based on national death registries and
xpert opinion. This figure is lower than the WHO  estimation [47],
ut it seems to be the closest to the country reality. Our estimation
or incidence of RVGE was higher than estimates of Bilcke et al. (0.31
er person-year), however we preferred to use our estimate which
s based on the local data from Iran and is also more compatible with
alker et al. systematic review on incidence of diarrhea in low and
iddle income countries [48,49]. We  obtained vaccine efficacy data
rom the international literature, using estimates from Latin Amer-
can and Asian countries with fairly high VE rates, so the efficacy
ight be different in Iranian patients. However, we  used data from
he same WHO  mortality stratum, B. Moreover, vaccine effective-
ess may  be lower than trial efficacy because of suboptimal vaccine
torage and administration and differences in disease epidemiol-
gy. We  assumed a 90% relative coverage of deaths because of
heir potential concentration among unvaccinated children; how-
ver, since the expected vaccine coverage is very high, this is a
essimistic assumption and real efficacy of vaccine for preventing
eaths should be higher. We  assumed vaccine coverage based on
hat for other vaccines, which may  not be an accurate estimation of
overage for the rotavirus vaccine. However, the majority of param-
ters with uncertain values could be tested in the scenario analysis
using high and low values). That testing showed that the results of
he base-case scenario were robust, and with most scenarios result-
ng in the vaccine being highly cost-effective or cost-effective. The
xception was the least favorable scenario. We  ran the model again
fter using a very low vaccine efficacy of 48.3% for full dose based
n the overall Vietnam and Bangladesh estimates from the Asian
tudy [29]. This led to an intervention that was still cost-effective
rom the government and societal perspective. Also, uncertainties
bout the VE of diverse genotypes of rotavirus have not been seen
n the literature [50,51].
We did not have access to the proportion of episodes of non-
evere diarrhea that are related to Rotavirus in the community
etting. We  used the proportion estimated through outpatient cases
or this purpose that might not be an exact assumption. We  did not
onsider the extra cost of visits by behvarz and health post offi-
er personnel, who are non-physician care providers (applicable
n 8.4% of cases of diarrhea where health care is sought). This was
ainly because of the type of their contract (fixed monthly salary)
nd available unused capacities in most parts of the health network.
e think that considering this opportunity cost would have a small
ffect on the cost-effectiveness profile in favor of doing vaccination.
Finally, it is evident that when allocating scarce community
esources, the adopted perspective should reach beyond that of
he provider (the health care system), which can be too restric-
ive. This study considered two different perspectives (societal and
overnment) but only direct medical cost was  included in the
ost estimation. Such other costs as productivity loss of the par-
nts, deceased cases due to diarrhea, and direct non-medical costs
ould change our results in the base-case analysis. However, we
re confident that our results are conservative and that the vaccine
ost-effectiveness profile in Iran probably would be better if we
ncluded those costs.. Conclusion
Due to the high morbidity and incidence of rotavirus diarrhea,
otavirus vaccine should be included in the Expanded Program on
[
Downloaded for Anonymous User (n/a) at Iran University of Medical Sciences from Clin
For personal use only. No other uses without permission. Copyright ©202033S (2015) A192–A200 A199
Immunization in Iran in the future. This cost-effectiveness analysis
demonstrated that introducing rotavirus vaccine into the program
could be highly cost-effective from the government and societal
perspective.
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